SummaryObjectives To assess the cost-effectiveness ratio of rifampin for 4 months and isoniazid for 6 months in contacts with latent tuberculosis infection. Methods The cost was the sum of the cost of treatment with isoniazid for 6 months or with rifampin for 4 months of all contacts plus the...
Rifampin chemoprophylaxis against Neisseria meningitidis infections led to the onset of rifampin resistance in clinical isolates harboring point mutations in the rpoB gene, coding for the RNA polymerase β chain. These resistant strains are rare in medical practice, suggesting their decreased fitness in ...
Interestingly, one of the isolates with the 14 amino acid long deletion acquired a three amino acid insertion close to the deletion (Table1). Insertions like this have not been seen in the evolution of amino acid substitution and might represent a type of “gap repair” mechanism in which th...
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung DiseaseEsfahani K, Aspler A, Menzies D, Schwartzman K. Potential cost-effectiveness of rifampin vs isoniazid for latent tuber- culosis: implications for future ...
Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection. Eur J Clin Microbiol Infect Dis 2013;32:647-655.Pina JM, et al. Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection...
105th International Conference of the American Thoracic Society: 1018, 17 May 2009Esfahani K , Aspler A , Menzies D , Schwartzman K . Rifampin versus isoniazid for treatment of latent tuberculosis: A cost-effectiveness analysis based on a multicenter clinical trial . American Journal of ...